NASDAQ:DYN
Dyne Therapeutics, Inc.
Dyne Therapeutics, Inc. reported net income of −$446.2M in fiscal 2025. Free cash flow was −$405.1M.Summary generated from Dyne Therapeutics, Inc.'s SEC filings. Latest annual report filed Mar 2, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROIC−175.3%
Return on equity−55.7%
Debt / equity0.15
Free cash flow−$405.1M
FCF marginn/a
Share count changen/a
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | n/a | n/a | n/a |
| Operating income | −150 | −171 | −242 | −344 | −468 |
| Net income | −149 | −168 | −236 | −317 | −446 |
| Free cash flow | −123 | −157 | −189 | −295 | −405 |
Recent filings
- 4Insider transaction report
Oct 6, 2026 - 8-KRegulation FD disclosure
Sep 29, 2026 - 4Insider transaction report
Sep 8, 2026 - 8-KResults of operations and financial condition
Jul 29, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Jul 29, 2026 - 8-KEntry into a material agreement
Jul 22, 2026 - 8-KOther events
Jul 20, 2026 - 8-KDirector or officer change
Jun 22, 2026